Loading clinical trials...

TERMINATED

Connect® MM- The Multiple Myeloma Disease Registry

NCT01081028•Celgene

Summary

The purpose of the Connect® MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) and provide unique insights into the management of MM and the impact of this hematologic disorder on patients.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Cohort 1 and 2
•Newly diagnosed with symptomatic MM within 2 months of enrollment in Connect® MM registry
•Age ≥18 years
•Willing and able to provide signed informed consent
•Agrees to complete patient assessment questionnaires either alone or with minimal assistance from caregivers and/or trained site personnel
•Cohort 3
•Received 1L therapy for symptomatic active MM and subsequently has evidence of disease progression. Prior 1L MM treatment received, including anti-myeloma therapy, transplant, chemotherapy, radiation, and surgery, must be known.
•Initiated or intends to initiate 2L systemic therapy for MM after the first documented relapsed/refractory date (i.e. 1L PD).
•Enrollment date must be within 90 days of start date (or intended start date) of 2L systemic therapy.

Exclusion Criteria

•Cohort 1 and 2
•\- None
•Cohort 3
•Patient's 1L MM treatment was for smoldering MM or MGUS, and not for symptomatic MM
•Currently active in any MM Registry, including but not limited to, the Connect® MM registry or another Celgene/BMS-Sponsored registry.
•Currently enrolled or intending to enroll within 90 days in any interventional clinical trial in which any treatment is an investigational product that cannot be identified

Locations (253)

The Cancer Center of Huntsville

Huntsville, Alabama, United States

DCH Health System

Tuscaloosa, Alabama, United States

US Oncology - Arizona Oncology Associates - Rudasill

Tucson, Arizona, United States

St. Edward Mercy Medical Center

Fort Smith, Arkansas, United States

Genesis Cancer Center

Hot Springs, Arkansas, United States

Clopton Clinic Hematology/Oncology

Jonesboro, Arkansas, United States

Little Rock Hematology Oncology Associates, PA

Little Rock, Arkansas, United States

Pacific Cancer Medical Center, Inc

Anaheim, California, United States

Alta Bates Summit Comprehensive Cancer Center

Berkeley, California, United States

Southbay Oncology Hematology Partners

Campbell, California, United States

Key Dates

Start Date

September 1, 2009

Primary Completion Date

December 31, 2024

Completion Date

December 31, 2024

Last Updated

August 3, 2025

Enrollment

3,008

ACTUAL participants

Conditions

Multiple Myeloma

Interventions

First-line therapy

OTHER

Second-line Multiple Myeloma treatments

DRUG

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

NCT06179888

Multiple Myeloma

View study

RECRUITINGPHASE3

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

NCT06152575

Multiple Myeloma

View study

RECRUITINGPHASE1/PHASE2

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 3, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Connect® MM- The Multiple Myeloma Disease Registry

Inclusion Criteria

Exclusion Criteria

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

Elranatamab in R/R Multiple Myeloma